138 related articles for article (PubMed ID: 10394541)
1. Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy.
Khurana KK; Singh SB; Tatum AH; Schulz V; Badawy SZ
J Reprod Med; 1999 Jun; 44(6):487-92. PubMed ID: 10394541
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
3. Fas and its ligand, caspases, and bcl-2 expression in gonadotropin-releasing hormone agonist-treated uterine leiomyoma.
Huang SC; Tang MJ; Hsu KF; Cheng YM; Chou CY
J Clin Endocrinol Metab; 2002 Oct; 87(10):4580-6. PubMed ID: 12364438
[TBL] [Abstract][Full Text] [Related]
4. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy.
Cohen D; Mazur MT; Jozefczyk MA; Badawy SZ
J Reprod Med; 1994 May; 39(5):377-80. PubMed ID: 7520497
[TBL] [Abstract][Full Text] [Related]
5. GnRH agonists before surgery for uterine leiomyomas. A review.
Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonist use before hysterectomy.
Stovall TG; Summit RL; Washburn SA; Ling FW
Am J Obstet Gynecol; 1994 Jun; 170(6):1744-8; discussion 1748-51. PubMed ID: 8203435
[TBL] [Abstract][Full Text] [Related]
7. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
[TBL] [Abstract][Full Text] [Related]
9. Leuprolide acetate treatment and myoma arterial size.
Rutgers JL; Spong CY; Sinow R; Heiner J
Obstet Gynecol; 1995 Sep; 86(3):386-8. PubMed ID: 7651647
[TBL] [Abstract][Full Text] [Related]
10. [Expression of bcl-2 protein in uterine leiomyomas and normal myometrium].
Zhang ZL; Zhang Y; Xu BQ
Hunan Yi Ke Da Xue Xue Bao; 2001 Aug; 26(4):363-5. PubMed ID: 12536738
[TBL] [Abstract][Full Text] [Related]
11. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).
Mizutani T; Sugihara A; Nakamuro K; Terada N
J Clin Endocrinol Metab; 1998 Apr; 83(4):1253-5. PubMed ID: 9543151
[TBL] [Abstract][Full Text] [Related]
12. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
[TBL] [Abstract][Full Text] [Related]
13. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
14. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
16. Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and FasL proteins in endometrial epithelial cell cultures from patients with endometriosis and controls.
Bilotas M; Barañao RI; Buquet R; Sueldo C; Tesone M; Meresman G
Hum Reprod; 2007 Mar; 22(3):644-53. PubMed ID: 17092985
[TBL] [Abstract][Full Text] [Related]
17. Potential cost savings using GnRH agonists as preoperative therapy for uterine leiomyomas.
Saltiel E
Formulary; 1995 Sep; 30(9):532-4, 542. PubMed ID: 10161243
[TBL] [Abstract][Full Text] [Related]
18. Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern.
Di Lieto A; De Falco M; Mansueto G; De Rosa G; Pollio F; Staibano S
Steroids; 2005 Feb; 70(2):95-102. PubMed ID: 15631865
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone.
Matsuo H; Maruo T; Samoto T
J Clin Endocrinol Metab; 1997 Jan; 82(1):293-9. PubMed ID: 8989276
[TBL] [Abstract][Full Text] [Related]
20. Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas.
Yoshida M; Ohtsuru A; Samejima T; Okazaki M; Fujishita A; Ito M; Yamashita S; Ishimaru T
Endocr J; 1999 Feb; 46(1):81-90. PubMed ID: 10426571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
